Povidone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11061 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | congenital ichthyosiform erythroderma | KG + DL |
| 2 | penile fibromatosis | KG + DL |
| 3 | self-healing collodion baby | KG + DL |
| 4 | palmar fibromatosis | KG + DL |
| 5 | Ledderhose disease | KG + DL |
| 6 | infantile digital fibromatosis | KG + DL |
| 7 | lamellar ichthyosis | KG + DL |
| 8 | bathing suit ichthyosis | KG + DL |
| 9 | Camurati-Engelmann disease | KG + DL |
| 10 | posterior leukoencephalopathy syndrome | KG + DL |
| 11 | bronchitis | KG + DL |
| 12 | carcinosarcoma | KG + DL |
| 13 | familial Dupuytren contracture | KG + DL |
| 14 | balanitis xerotica obliterans | KG + DL |
| 15 | aortic valve insufficiency | KG + DL |
| 16 | nephrosclerosis | KG + DL |
| 17 | geleophysic dysplasia | KG + DL |
| 18 | IgA glomerulonephritis | KG + DL |
| 19 | balanoposthitis | KG + DL |
| 20 | IgA nephropathy, susceptibility to | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.